Articles from Biostate AI

Harvard Medical School aging study demonstrates Biostate’s AI agent achieves industry-leading accuracy while accelerating biological discovery from years to days

The biotechnology startup has secured strategic research partnerships in the U.S. and India, and a joint venture in China, dramatically expanding the global dataset for their RNA sequencing-based precision medicine solutions.

The company is reimagining the fragmented reality of molecular research by building the world’s largest RNA sequencing dataset. This dataset will train a general-purpose AI to understand—and eventually guide therapies for—all human diseases.

Biostate AI, a leading innovator in artificial intelligence for RNA sequencing, and Weill Cornell Medicine have entered into a strategic collaboration to develop AI for personalized assessments of patient disease prognosis and evolution. Initially, the collaboration will focus on leukemia, leveraging the Weill Cornell Leukemia Program’s vast biorepository of bone marrow and blood samples.

Biostate AI, a leading innovator in artificial intelligence for RNA sequencing, today announced a strategic partnership with the Accelerated Cure Project (ACP), a nonprofit organization dedicated to accelerating research and improving outcomes for people with multiple sclerosis (MS). The partnership aims to develop next-generation AI models capable of predicting disease progression and treatment response in MS, leveraging transcriptomic data from ACP’s extensive biorepository.

Biostate AI, the scalable biodata foundry startup, emerges from stealth today with the launch of two service products: Total RNA sequencing and Copilot for RNAseq data analysis. Biostate AI aims to partner and collaborate with academic researchers, hospital biorepositories, and pharma/biotech companies, leveraging its new technologies for scalable multiomic data collection, scientific discovery, and AI training.